Longeveron (LGVN) Capital Expenditures (2020 - 2025)
Longeveron (LGVN) recorded quarterly Capital Expenditures of $57000.0 in Q3 2025, down 64.6% quarter-over-quarter from $161000.0 in Q2 2025, and down 86.74% on a YoY basis from $430000.0 in Q3 2024.
Longeveron (LGVN) Capital Expenditures (2020 - 2025) Analysis & Trends
Longeveron's Capital Expenditures history runs 6 years deep, the most recent figure standing at $57000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures fell 86.74% year-over-year to $57000.0; the TTM figure through Mar 2026 stood at $218000.0 (down 67.27% YoY), while the FY2025 annual figure was $245000.0, down 62.6% from the prior year.
- Capital Expenditures was $57000.0 for Q3 2025 at Longeveron, down from $161000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $430000.0 in Q3 2024 to a low of $3000.0 in Q3 2023.
- Historically, Capital Expenditures has averaged $130125.0 across 5 years, with a median of $72000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures sank 99.21% in 2023, then jumped 14233.33% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $312000.0 in 2021, then plunged by 78.85% to $66000.0 in 2022, then jumped by 148.48% to $164000.0 in 2023, then slumped by 92.07% to $13000.0 in 2024, then jumped by 338.46% to $57000.0 in 2025.
- The last three Capital Expenditures figures came in at $57000.0 (Q3 2025), $161000.0 (Q2 2025), and $27000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 57,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 430,000.00 |
| Sep 30, 2024 | 430,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 92,000.00 |
| Jun 30, 2023 | 92,000.00 |